Homology Medicines Inc. Stock News

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

Homology Medicines (NASDAQ:FIXX)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a research report issued on Friday, TipRanks reports. They currently have a

Homology Medicines (NASDAQ:FIXX)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Friday, TipRanks reports. They currently have a $36.00 price target on the stock

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Homology Medicines

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Homology Medicines (FIXX) with

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma ( AERI – Research Report ) and Homology Medicines ( FIXX – Research Report ) with bull

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Homology Medicines (FIXX) and X4 Pharmaceuticals (XFOR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Homology Medicines

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines Inc:

BEDFORD, Mass. (AP) _ Homology Medicines Inc. (FIXX) on Thursday reported a loss of $24.2 million in its fourth quarter. The Bedford, Massachusetts-based company said it had a loss of 55 cents per sh

- Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently Controlled Expansion.

- Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently...